Chromadex Profit Margin

Chromadex (CDXC) currently reports a profit margin of 53.69% as of June 2026. That compares with 27.68% in the prior-year period — up 93.9% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Chromadex's profit margin history and peer comparisons.

Chromadex's profit margin increased from 27.68% to 53.69% — a 93.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromadex's profit margin of 53.69% is higher than the Healthcare sector average of 13.89%. That is roughly 286.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Chromadex's current 53.69% should be judged against Healthcare norms (sector average: 13.89%) and against CDXC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 53.69%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Chromadex, and consider following CDXC for alerts when major investors trade the stock.